By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Markets > Stocks > Amgen agrees not to seek quick close to Horizon acquisition
Stocks

Amgen agrees not to seek quick close to Horizon acquisition

News Room
Last updated: 2023/05/19 at 12:30 AM
By News Room
Share
2 Min Read
SHARE

© Reuters. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith

WASHINGTON (Reuters) – Amgen Inc (NASDAQ:) has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics (NASDAQ:) after the U.S. Federal Trade Commission (FTC) filed suit to block the deal.

A U.S. district court judge issued a temporary restraining order late on Wednesday after the two companies and the FTC reached an agreement that both sides said in a joint filing would permit a full briefing and “less-compressed consideration” by the court of the FTC request.

Absent an agreement, Amgen could have sought to close the deal as early as Monday.

Under the order, Amgen and Horizon will not close their transaction until the earlier of Sept. 15, or the second business day after the court rules on the FTC’s request for a preliminary injunction.

California-based Amgen, which had earlier hoped to close the deal in the first half of this year, had said on Tuesday it would work with the court in a bid to complete the transaction by mid-December.

In its lawsuit the FTC said it believed Amgen could leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to favor Horizon’s two key products – the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa – over potential competitors.

Amgen said it had made an offer to the FTC in the hope of resolving the issue. “We committed that we would not bundle the Horizon products raised as issues,” Amgen said in a statement.

Reuters reported on Thursday that the FTC faces an uphill battle in its fight against the deal with an untested argument, three antitrust experts said.

Read the full article here

News Room May 19, 2023 May 19, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Trump threatens 30% tariffs on EU and Mexico, bitcoin tops $122K

Watch full video on YouTube

We Went To Canada To See The U.S. Product Boycotts — And What We Found Was Striking

Watch full video on YouTube

Bitcoin tops $123K, another S&P 500 target boost, Trump’s latest tariff wrath hits Mexico and the EU

Watch full video on YouTube

Why Applebee’s is struggling while Chili’s thrives

Watch full video on YouTube

Truist Financial Corporation (TFC) Q2 2025 Earnings Call Transcript

Truist Financial Corporation (NYSE:TFC) Q2 2025 Earnings Conference Call July 18, 2025…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

CPS reports solid 2023 performance, eyes future growth By Investing.com

By News Room
Stocks

Niu Technologies faces mixed results in Q4 2023 By Investing.com

By News Room
Stocks

Exagen Inc. reports strong 2023 revenue growth By Investing.com

By News Room
Stocks

Legacy Housing reports mixed results amid sales decline By Investing.com

By News Room
Stocks

Harmony Biosciences exec sells over $383k in stock By Investing.com

By News Room
Stocks

Biofrontera posts record revenue and outlines growth plans By Investing.com

By News Room
Stocks

Granite Ridge CFO buys $31,000 in company stock By Investing.com

By News Room
Stocks

Coliseum Capital Management buys MasterCraft Boat shares worth over $3.2m By Investing.com

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?